To learn more about Cytimmune, contact us.

Company Overview

Cytimmune Sciences is an oncology company with operations and personnel in Rockville, Maryland, and Boston, Massachusetts. The company was founded in 1988 as a research diagnostics supplier with expertise in immune system components including cytokine and antibody production, detection, and manipulation. Cytimmune technologies reincorporated as a Delaware company in 2004 to focus on innovative cancer therapeutics. The company published results from its first clinical trial in 2010. Cytimmune has won multiple National Institute of Standards and Technology and Small Business Innovation Research grants to develop an oncology therapeutics platform and supporting technologies.

Technology Overview

The company’s oncology platform (IO+) is a virus-sized, engineered delivery vector designed to support safer, more effective combination therapies including current and future immuno-therapeutics, precision, and other enhanced anti-cancer therapeutics. The core platform includes high-dose TNF alpha, a powerful immunomodulatory cytokine with multiple anti-cancer, anti-tumor effects, the use of which has previously been limited due to systemic toxicity. Our data from animal and human studies show our platform enables safer and more effective combination therapies.

Recent News and Updates

Featured
NCL signs MTA with Cytimmune Sciences for novel nanomedicine
NCL signs MTA with Cytimmune Sciences for novel nanomedicine

Cytimmune and the U.S. Nanotechnology Characterization Laboratory (NCL) have signed a Material Transfer Agreement (MTA). The focus of this agreement is a new nanomedicine construct developed by Cytimmune that simultaneously delivers Interferon gamma (IFN-y) and Tumor Necrosis Factor alpha (TNF alpha) on the same gold nanoparticle. Cytimmune will supply newly formulated therapeutic to the NCL for in vitro studies and characterization. Studies are expected to be initiated in 2021.

Tokyo University of Science Signs Research Agreement with Cytimmune Sciences to Investigate IO+ nanomedicines in combination with checkpoint inhibitors.
Tokyo University of Science Signs Research Agreement with Cytimmune Sciences to Investigate IO+ nanomedicines in combination with checkpoint inhibitors.

CytImmune has signed an agreement with the Tokyo University of Science, Division of Molecular Regulation of Inflammation and Immune diseases to investigate and confirm synergies between TNF alpha and existing immunotherapies.

NCI to Conduct Phase 2 Studies of Cytimmune’s lead nanomedicine, CYT-6091
NCI to Conduct Phase 2 Studies of Cytimmune’s lead nanomedicine, CYT-6091

CytImmune has signed a Clinical Trial Agreement with the National Cancer Institute to conduct clinical studies to include a Phase 2 trial of CytImmune’s lead therapeutic construct, CYT-6091.

Clinical studies will be conducted by Dr. Naris Nilubol, an oncologist and surgeon leading the NCI’s endocrine oncology branch.

List of Key Scientific Publications